|
|
Volumn 51, Issue 2, 2001, Pages 177-180
|
|
Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients
a
|
|
Author keywords
Cancer patients; Fibroblast activation protein; mAbF19; Monoclonal antibody; Population pharmacokinetics
|
|
Indexed keywords
CANCER ANTIBODY;
FIBROBLAST ACTIVATION PROTEIN;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY F19 I 131;
TUMOR ANTIGEN;
UNCLASSIFIED DRUG;
ADULT;
AGED;
ARTICLE;
CANCER IMMUNOTHERAPY;
CLINICAL ARTICLE;
CLINICAL TRIAL;
COLORECTAL CARCINOMA;
COMPARTMENT MODEL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG CLEARANCE;
DRUG DISTRIBUTION;
DRUG HALF LIFE;
FEMALE;
HUMAN;
ISOTOPE LABELING;
MALE;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
SOFT TISSUE SARCOMA;
ADULT;
AGED;
ANTIBODIES, MONOCLONAL;
ANTIGENS, NEOPLASM;
ANTINEOPLASTIC AGENTS;
FEMALE;
GROWTH SUBSTANCES;
HUMANS;
MALE;
MIDDLE AGED;
NEOPLASMS;
SERINE ENDOPEPTIDASES;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 0035105854
PISSN: 03065251
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1365-2125.2001.01335.x Document Type: Article |
|
Times cited : (38)
|
|
References (12)
|
